he continuing emergence of immune-evasive variants of SARS-CoV-2 virus represents a major challenge in controlling COVID-19 pandemic disease. Researchers from Stanford University have tested the immunogenicity and protective effect of the receptor binding domain (RBD)-I53-50 AS03-adjuvanted nanoparticle vaccine in nonhuman primates.